A physician explains that the sale of nonprescription cosmeceuticals from a dermatology office should be done in a manner that is educational but non-threatening to patients.
A physician and a lawyer argue against a dermatology clinic switching from a small, reliable pathology lab to a large-scale pathology lab in order to receive volume discounts and increase profit.
A physician responds to a previous article about the differences between using a commercial laboratory and a smaller hospital or pathology group lab for dermatological tests.
Explanation of the Medicare and Medicaid Antikickback statute and Stark Law and their restrictions on physicians' financial interests in ancillary services.
Guidelines for proceeding with a plan of care when family members have conflicting opinions about the patient’s wishes and the patient does not speak the same language as her physicians.
Dr Elizabeth Salisbury-Afshar joins Ethics Talk to discuss her article, coauthored with Drs Catherine J. Livingston and Ricky N. Bluthenthal: “How Should Harm Reduction Be Included in Care Continua for Patients With Opioid Use Disorder?”
Dr Kelly Gillespie joins Ethics Talk to discuss her article, coauthored with Dr Taleed El-Sabawi: “When Medication Treatment for Opioid Use Disorder Gets Disrupted by Extra-Clinical Variables, How Should Clinicians Respond?”